The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Advancements in treating MCL
Eva Giné, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses novel treatments for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T‐cell therapies have recently gained traction and several CAR T-cell therapies have been approved for use in patients with MCL. Additional trials are being conducted to assess combination immunotherapies, improving the treatment landscape, where patients who progress from current treatment represent an unmet clinical need. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
